Novartis Extends Malaria Partnership to Develop New Drug Candidate
June 15, 2016
Novartis has announced that is to further expand its partnership with Medicines for Malaria Venture (MMV). The drugmaker will lead the development of antimalarial compound KAF156 -- one of the first antimalarial drug candidates to enter Phase IIb clinical development in more than 20 years -- with scientific and financial support from MMV in collaboration with the Bill & Melinda Gates Foundation.
KAF156 acts against the two parasites responsible for the majority of malaria deaths (Plasmodium falciparum and Plasmodium vivax) and against both the blood and liver stages of the parasite’s lifecycle.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
